Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SRX3212 is a Novel BRD4/PI3Kα inhibitor, displaying an IC50 of 3.7 nM toward BRD4BD1 and 32 nM toward BRD4BD2, and therefore was~65-fold more potent inhibitor of BRD4BD1 and~48-fold more potent inhibitor of BRD4BD2 than SF2523 (GLXC-10641), retaining its high inhibitory activity for PI3Kα (IC50: 22 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | SRX3212 is a Novel BRD4/PI3Kα inhibitor, displaying an IC50 of 3.7 nM toward BRD4BD1 and 32 nM toward BRD4BD2, and therefore was~65-fold more potent inhibitor of BRD4BD1 and~48-fold more potent inhibitor of BRD4BD2 than SF2523 (GLXC-10641), retaining its high inhibitory activity for PI3Kα (IC50: 22 nM). |
Molecular Weight | 505.54 |
Formula | C26H23N3O6S |
CAS No. | 2735720-80-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SRX3212 2735720-80-4 SRX-3212 SRX 3212 inhibitor inhibit